This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Radiation Therapy  • Ocular/ Adnexal Tumors  • Enucleation  • Alert me on articles by topic

Findings From Patients Examined at Collaborative Ocular Melanoma Study (COMS) Centers: COMS Report No. 20

Collaborative Ocular Melanoma Study Group^*

Arch Ophthalmol. 2003;121:1156-1162.

Objective  To describe time trends, from 1987 through 1997, (1) in size of choroidal melanoma among patients with recent diagnosis confirmed at a clinical center that participated in the Collaborative Ocular Melanoma Study (COMS) and (2) in choice of treatment by patients who did not enroll in one of the COMS randomized trials.

Methods  Investigators at all COMS clinical centers (41 in the United States and 2 in Canada) agreed to report, in a masked fashion that did not include personal identifiers, all patients diagnosed as having choroidal melanoma during the accrual period for COMS randomized trials of radiotherapy. Information reported for patients who did not enroll in a COMS randomized trial included tumor dimensions, date of diagnosis, and initial treatment selected. Patients reported by centers that continued to report cases until 1997 and diagnosed as having choroidal melanoma no more than 1 year before evaluation at a participating COMS center contributed the data analyzed.

Outcome Measures  Time trends in tumor size among patients reported and in elective treatment of patients not enrolled in COMS randomized trials.

Results  Of 8712 patients with choroidal melanoma examined, 6703 met criteria for analysis of time trend in tumor size and 4077 were analyzed for treatment trends over time. The number of cases with longest tumor basal diameter greater than 15.0 mm declined over time from 393 (30%) of 1330 cases reported in 1987 through 1989 to 345 (25%) of 1397 cases reported in 1996 or 1997. The proportion of patients eligible for COMS randomized trials who did not enroll and who elected enucleation remained stable over time for tumors of all sizes; the proportion of these patients who elected eye-conserving radiotherapy increased over time. Juxtapapillary tumors accounted for nearly half of the enucleations among ineligible patients who had tumors no larger than 15.0 mm in longest basal diameter.

Conclusions  Among patients examined at COMS centers during 1987 through 1997, the trends observed for patients with recently diagnosed choroidal melanoma included increasing presentation with tumors of smaller size, decreasing use of enucleation for choroidal melanoma 15.0 mm or less in longest basal diameter, and increasing use of such strategies for larger tumors.

^*This report was prepared on behalf of the COMS Group by Barbara S. Hawkins, PhD; Sandra M. Reynolds, MA; Marie Diener-West, PhD; John D. Earle, MD; Rosemary A. Hollick, MS; Marta J. Marsh, MS; B. Michele Mela, ScM; and Andrew P. Schachat, MD. A complete list of the members of the Collaborative Ocular Melanoma Study Group as of September 30, 2000, was published in Arch Ophthalmol. 2001;119:951-965. The authors have no relevant financial interest in this article.

RELATED ARTICLE

Comparison of Clinical, Echographic, and Histopathological Measurements From Eyes With Medium-Sized Choroidal Melanoma in the Collaborative Ocular Melanoma Study: COMS Report No. 21
Collaborative Ocular Melanoma Study Group
Arch Ophthalmol. 2003;121(8):1163-1171.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Plaque Radiotherapy for Choroidal Melanoma Encircling the Optic Disc (Circumpapillary Choroidal Melanoma)
Sagoo et al.
Arch Ophthalmol 2007;125:1202-1209.
ABSTRACT | FULL TEXT  

How do you know?
Rosenbaum et al.
Br. J. Ophthalmol. 2004;88:980-981.
FULL TEXT